Hims & Hers Says FTC Lawsuit Disregards Substantial Evidence We Provided the Agency During Investigation

Hims & Hers Health on FTC Lawsuit : We are Confident in Our Position and Will Vigorously Defend Ourselves Against These Baseless Claims

Rpt: Hims & Hers on FTC Lawsuit: Lawsuit Disregards Substantial Evidence We Provided the FTC During Its Nearly Three-Year Investigation

FTC Suing Hims & Hers Health for Allegedly Sending User Info to Meta and Snap, Reuters Reports

Hims & Hers Shares Down 12.2%; Reuters Reports US FTC Sues Co for Sending User Health Info to Meta, Snap

US FTC Suing Hims & Hers for Sending User Health Info to Meta, Snap

Exclusive - U.S. Federal Trade Commission is Suing Hims & Hers over Billing, Cancellation and Privacy Practices, FTC Spokesperson Says

Hims & Hers Health (HIMS) Receives a Hold from Truist Financial

Is Today’s Dip a Buying Opportunity for Hims & Hers Health (HIMS) Stock?

Hims & Hers falls -10.3%

Truist Raises Price Target on Hims & Hers Health to $27 From $23, Keeps Hold Rating

Hims & Hers Health Inc : Truist Securities Raises Target Price to $27 from $23

Moderately bullish activity in Hims and Hers Health with shares up 3.39%

Hims & Hers Health is Maintained at Neutral by Citigroup

FDA Advisers Back First Four of Seven Unapproved Peptides Under Review for Looser Rules

Hims Gains After FDA Panel Votes to Place Popularly Used Peptide Bpc-157 on Compounding List

Hims & Hers Health Shares up 10% After FDA Advisory Panel Votes to Place Bpc-157 Peptide on Allowed Pharmacy Compounding List

Hims & Hers Shares up 2% After Telehealth Firm Urged FDA to Broaden Access to Some Peptides in Panel Meeting

Peptides Could Soon Become Widely Available in the U.S. Here's What Happens Next.